Get the Stockscreener App
21.43
0.30%
-0.075
Intellia Therapeutics Inc stock is currently priced at $21.43, with a 24-hour trading volume of 776.26K.
It has seen a -0.30% decreased in the last 24 hours and a -21.68% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $21.69 pivot point. If it approaches the $21.25 support level, significant changes may occur.
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Intellia Therapeutics Inc (NTLA) Revenue 2024
NTLA reported a revenue (TTM) of $36.27 million for the quarter ending December 31, 2023, a -30.40% decline year-over-year.
Intellia Therapeutics Inc (NTLA) Net Income 2024
NTLA net income (TTM) was -$481.19 million for the quarter ending December 31, 2023, a -1.48% decrease year-over-year.
Intellia Therapeutics Inc (NTLA) Cash Flow 2024
NTLA recorded a free cash flow (TTM) of -$408.07 million for the quarter ending December 31, 2023, a -4.19% decrease year-over-year.
Intellia Therapeutics Inc (NTLA) Earnings per Share 2024
NTLA earnings per share (TTM) was -$5.41 for the quarter ending December 31, 2023, a +12.46% growth year-over-year.
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '24 |
Sale |
32.99 |
605 |
19,959 |
71,470 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 08 '24 |
Sale |
28.87 |
2,275 |
65,682 |
43,927 |
| LEONARD JOHN M | President and CEO |
Jan 03 '24 |
Sale |
29.46 |
19,223 |
566,310 |
846,486 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '24 |
Sale |
29.46 |
5,843 |
172,135 |
54,372 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '24 |
Sale |
29.46 |
5,532 |
162,973 |
46,202 |
| Goddard Glenn | EVP, Chief Financial Officer |
Jan 03 '24 |
Sale |
29.46 |
5,365 |
158,053 |
40,585 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 03 '24 |
Sale |
29.50 |
4,608 |
135,954 |
40,845 |
| Hicks Derek | EVP, Chief Business Officer |
Jan 03 '24 |
Sale |
29.46 |
3,877 |
114,216 |
36,987 |
| BASTA JAMES | EVP, General Counsel |
Jan 03 '24 |
Sale |
29.46 |
3,805 |
112,095 |
51,474 |
| Bhanji Muna | Director |
Oct 31 '23 |
Sale |
23.90 |
265 |
6,334 |
11,996 |
Intellia Therapeutics Inc Stock (NTLA) Latest News
2 Stocks Down 30% to Buy Right Now
The Motley Fool
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The Motley Fool
Better Cathie Wood Stock: Moderna vs. Intellia
The Motley Fool
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Zacks Investment Research
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
GlobeNewswire Inc.
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
COMPANY PROFILE
NameIntellia Therapeutics Inc
SectorHealthcare (1198)
IndustryBiotechnology (689)
Web
Phone857-285-6200
Employee195
Twitter
@intelliatweets
SEC filings
Latest SEC Filings
Next earning date2024-05-02
Address40 Erie Street, Suite 130, Cambridge, MA, United States (2139)
0.77%
0.13%
Cap:
|
Volume (24h):